Project Management Standards Applied to Complex Clinical Trials. Disclaimer

Size: px
Start display at page:

Download "Project Management Standards Applied to Complex Clinical Trials. Disclaimer"

Transcription

1 Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2

2 Topics Typical Issues in Clinical Trials Project Management Standards Some Project Management Standards Key Knowledge Areas PM Standards and Clinical Trials Summary 3 Typical Issues with Clinical Trials Duration and Cost exceeded Too many uncertainties (assumptions) No effective cost control No effective schedule control Reactive Risk Management Risks are addressed too late Risk prevention is not a team effort No budget for contingencies 4

3 Typical Issues with Clinical Trials Quality Issues Quality issues detected late, e.g. systematic protocol violations prior to DB lock, or data issues detected once statistical analysis was completed Communication and Team Issues Rare and ineffective meetings No ongoing training 5 Typical Issues with Clinical Trials Frequent Scope Changes Stakeholders requests Regulatory requirements Marketing requirements Misunderstandings between sponsor and service providers regarding activities contained in agreed upon working packages / tasks 6

4 Project Management Standards PMBOK Project Management Body of Knowledge ICB International Competence Baseline PRINCE2 Projects In Controlled Environments Several national and industry specific standards 7 Project Management Standards Key PM Knowledge Areas: Scope Time Budget Human Resources Quality Communication and Stakeholders Risk Procurement Project Integration Integration of all areas Change control 8

5 PM Standards and Clinical Trials The well known PM standards (PMBOK, ICB, PRINCE2, etc.) are not industry specific Clinical trials are fully featured projects, having all characteristics of a typical project. 9 PM Standards and Clinical Trials Are the typical issues of clinical trials addressed by the key PM knowledge areas? Duration and Cost exceeded Reactive Risk Management Quality Issues Communication and Team Issues Frequent Scope Changes 10

6 Key Principles from PM Standard All Projects Are Unique There s no standard project plan which will perfectly fit. But it is useful to use plans of similar projects as templates. Project management team is responsible for defining project specific procedures, processes, planning detail and strategies, in the context of the performing organization. 11 Key Principles from PM Standard Monitoring & Controlling Processes Planning Processes Initiating Processes Closing Processes Executing Processes The Deming Wheel (Plan-Do-Check-Act Cycle) 12

7 Key Principles of PM Standards Planning is key for a successful execution of the project as well as for successful change control Planning how to plan is key for a good project plan! 21 out of 44 PMBOK processes are about planning 13 Summary Clinical Trials are projects and should be managed as such The most known project management standards are not industry specific. They can be applied to clinical projects and will address all of the recurring issues Good project planning is the key for success! 14

8 Any Questions? 15 Thank You Very Much! 16

High Quality or Poor Quality DB

High Quality or Poor Quality DB The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,

More information

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

QPPV Association and Training Part 2 Session Introduction

QPPV Association and Training Part 2 Session Introduction QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are

More information

Promotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company

Promotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the

More information

SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs

SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides

More information

Do Niche CROs have a Role in Drug Development?

Do Niche CROs have a Role in Drug Development? Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials

Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials H.M. James Hung, Ph.D Div. of Biometrics I, OB/OTS/CDER U.S. Food and Drug Administration Presented in PhRMA/FDA Workshop, October 28,

More information

Update on New MedDRA SOC Product issues

Update on New MedDRA SOC Product issues Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following

More information

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The

More information

General Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria

General Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria EDC-System Selection From the point of view of small to mid-size CROs Steffen König General Manager IST GmbH - Mannheim 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

Pharmacovigilance Post July 2012 The new frontier

Pharmacovigilance Post July 2012 The new frontier Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The

More information

Into the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith

Into the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in

More information

Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer

Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The

More information

Labelling Harmonization 2011

Labelling Harmonization 2011 Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

esource What EDC Should Be Presenter: Ed Seguine President

esource What EDC Should Be Presenter: Ed Seguine President esource What EDC Should Be Presenter: Ed Seguine President The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

Project Management Competencies. Disclaimer 28/06/2011

Project Management Competencies. Disclaimer 28/06/2011 Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions

More information

Effective Project Leadership and Management: Disclaimer

Effective Project Leadership and Management: Disclaimer Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following

More information

Using etechnologies to Increase Efficiency and Quality in Regulatory Operations

Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following

More information

Delivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens

Delivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

Hands-on in Latin America Regulations for Clinical Trials

Hands-on in Latin America Regulations for Clinical Trials Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following

More information

What is an ideal PSUR? A new focus based on aligned expectations

What is an ideal PSUR? A new focus based on aligned expectations What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views

More information

QbD Approach and Regulatory Challenges in Japan

QbD Approach and Regulatory Challenges in Japan QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria

More information

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd

More information

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following

More information

Pharmacovigilance in Asia: The China Perspectives. Disclaimer

Pharmacovigilance in Asia: The China Perspectives. Disclaimer Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in

More information

Sharing Regulatory Intelligence: Best Practices and Case Studies

Sharing Regulatory Intelligence: Best Practices and Case Studies Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria

More information

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed

More information

Eugène van Puijenbroek, MD, PhD

Eugène van Puijenbroek, MD, PhD Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed

More information

PM tutor. The Business Case, SOW and The Project Charter. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence

PM tutor. The Business Case, SOW and The Project Charter. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence PM tutor Empowering Excellence The Business Case, SOW and The Project Charter Presented by Dipo Tepede, PMP, SSBB, MBA This presentation is copyright 2009 by POeT Solvers Limited. All rights reserved.

More information

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA) DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance

More information

PROJECT MANAGEMENT PLAN INTRODUCTION. 1 Powered by POeT Solvers Limited

PROJECT MANAGEMENT PLAN INTRODUCTION. 1   Powered by POeT Solvers Limited PROJECT MANAGEMENT PLAN INTRODUCTION 1 www.pmtutor.org Powered by POeT Solvers Limited This presentation is copyright 2013 by POeT Solvers Limited. All rights reserved. This presentation is protected by

More information

Development of Orphan Drugs Regulatory Viewpoints from PMDA

Development of Orphan Drugs Regulatory Viewpoints from PMDA Development of Orphan Drugs Regulatory Viewpoints from PMDA Ken Sakushima Office of Cellular and Tissue-based Products, Office of New Drug III Pharmaceuticals and Medical Devices Agency (PMDA) Disclaimer

More information

How to successfully Implement and Leverage the Regulatory Intelligence Function

How to successfully Implement and Leverage the Regulatory Intelligence Function How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,

More information

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation

More information

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Modeling and Simulation for Dose Selection using Adaptive Designs

Modeling and Simulation for Dose Selection using Adaptive Designs Modeling and Simulation for Dose Selection using Adaptive Designs Nitin Patel Chairman and C.T.O. Cytel, Inc. Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance

More information

PMDA Update. - New Regulation in Japan and Future Direction of PMDA

PMDA Update. - New Regulation in Japan and Future Direction of PMDA PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and

More information

Data standardization and advancing regulatory science

Data standardization and advancing regulatory science Data standardization and advancing regulatory science Yoshiaki Uyama, Ph.D. Pharmaceuticals & Medical Devices Agency (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor,

More information

Structured Content Management [SCM]

Structured Content Management [SCM] Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint

More information

Procedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011

Procedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Harmonization of Labeling Across Products with Same Active Moiety in the EU Procedures in Regard to Entire Product Information Texts Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Disclaimer The

More information

Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach

Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Peter Lassoff, PharmD, FTOPRA VP & Head, Global Regulatory Affairs IQVIA Disclaimer The views and opinions expressed

More information

The views and opinions expressed in the following PowerPoint slides are

The views and opinions expressed in the following PowerPoint slides are Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views

More information

PMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA

PMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed

More information

Project Management Training Brochure

Project Management Training Brochure Project Management Training Brochure We develop project management training sessions by integrating our 40 years of combined practitioner experience with the most current project management knowledgebase

More information

Labelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines

Labelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe

More information

Human Vss Prediction. James Yates AstraZeneca. Disclaimer 10/25/2011

Human Vss Prediction. James Yates AstraZeneca. Disclaimer 10/25/2011 0/25/20 Human Vss Prediction Part 2: Comparative Assessment of Prediction Methods of Human Volume of Distribution R.D.O JONES,H.M. JONES, M. ROWLAND, C.R. GIBSON, J.W.T. YATES, J.Y. CHIEN, B. J. RING,

More information

Drug development and evaluation with small clinical Trials from the regulatory point of view

Drug development and evaluation with small clinical Trials from the regulatory point of view Drug development and evaluation with small clinical Trials from the regulatory point of view Harumasa Nakamura, M.D. Deputy Review Director Office of New Drug III Pharmaceuticals and Medical Devices Agency

More information

Stakeholder education on biosimilar concepts - why does it matter globally?

Stakeholder education on biosimilar concepts - why does it matter globally? Stakeholder education on biosimilar concepts - why does it matter globally? Dr Virginia Acha Director, Regulatory Policy Europe, Middle East and Africa Amgen 26th Annual EuroMeeting 25-27 March 2014 ACV,

More information

PMBOK Guide Sixth Edition Updates and Agile Alignment By Tony Johnson July 2017

PMBOK Guide Sixth Edition Updates and Agile Alignment By Tony Johnson July 2017 PMBOK Guide Sixth Edition Updates and Agile Alignment By Tony Johnson July 2017 Trademarks and Copyrights Materials in this presentation are based on the text, A Guide to the Project Management Body of

More information

Regulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation

Regulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation Regulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation Dr Yoshiaki Uyama Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions

More information

Implementation of EU Falsified Medicines Directive

Implementation of EU Falsified Medicines Directive Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10 CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

NAS and KAS Industry perspective

NAS and KAS Industry perspective NAS and KAS Industry perspective Henk Schuring Group Vice President Regulatory Affairs Europe Genzyme Europe BV, Netherlands 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The

More information

Current Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals

Current Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals 15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current

More information

Overview of A Guide to the Project Management Body of Knowledge (PMBOK Guide) Fourth Edition Changes

Overview of A Guide to the Project Management Body of Knowledge (PMBOK Guide) Fourth Edition Changes Overview of A Guide to the Project Management Body of Knowledge (PMBOK Guide) Fourth Edition Changes PMI -- Project Management Institute» Leading global association for the project management profession»

More information

Project Management Body of Knowledge (PMBoK)

Project Management Body of Knowledge (PMBoK) Project Management Body of Knowledge (PMBoK) Knowledge & Practice Areas Project Management PMBoK Prince 2 ISO 10006 General Management Application high performance sport 2 Theory vs. Practice: A Disclaimer

More information

Guten Tag. (good day)

Guten Tag. (good day) Guten Tag (good day) 4.5 Perform Integrated Change Control How a person may percieve change: paideiagroup.com 4.5 Perform Integrated Change Control Consider what change is: Crossing unknown territory Departing

More information

Trial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1

Trial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Trial Master File Reference Model Project Charter Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Prepared by The Exchange Mechanism Standard Subgroup of the TMF Reference

More information

How to Implement a Successful e-archiving Function Within a Multinational Company

How to Implement a Successful e-archiving Function Within a Multinational Company How to Implement a Successful e-archiving Function Within a Multinational Company Huguette BESSARD Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

The Patient-Reported Outcome (PRO) Consortium:

The Patient-Reported Outcome (PRO) Consortium: The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the

More information

Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines

Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Richard Dolinar, MD Chairman, Alliance for Safe Biologic Medicines Disclaimer The views and opinions expressed

More information

Project Management for Non-Profits What s in it for you? Benefits of Improved Project Management (PM) Skills, Techniques and Processes.

Project Management for Non-Profits What s in it for you? Benefits of Improved Project Management (PM) Skills, Techniques and Processes. Project Management for Non-Profits What s in it for you? Benefits of Improved Project Management (PM) Skills, Techniques and Processes Nov 2014 1 Overview What is a project? Impact on organizational results

More information

Project Management Process Groups. PMP Study Group Based on the PMBOK Guide 4 th Edition

Project Management Process Groups. PMP Study Group Based on the PMBOK Guide 4 th Edition Project Management Process Groups PMP Study Group Based on the PMBOK Guide 4 th Edition Introduction PM Process Groups In order for a project to be successful, the project team must: Select appropriate

More information

Regulatory Perspectives on NGS-based CDx

Regulatory Perspectives on NGS-based CDx 14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake Regulatory Perspectives on NGS-based CDx Reiko Yanagihara, Ph.D. Office of In Vitro Diagnostics Deputy Review Director Pharmaceuticals

More information

INTEGRATION of PROJECT MANAGEMENT and SYSTEMS ENGINEERING

INTEGRATION of PROJECT MANAGEMENT and SYSTEMS ENGINEERING Copyright 2018 by Yves Theriault. Permission granted to INCOSE to publish and use. INTEGRATION of PROJECT MANAGEMENT and SYSTEMS ENGINEERING San Diego INCOSE Mini-Conference December 1, 2018 John Wood,

More information

Project Management Session 6.2. Project Initiation Phase Integration Management

Project Management Session 6.2. Project Initiation Phase Integration Management Project Management Session 6.2 Project Initiation Phase Integration Management 1 Project Phases & Knowledge Areas 1. Integration 2. Scope Management 3. Time Management 4. Cost Management 5. Quality Management

More information

Falcon Training PMP & CAPM Exam Preparation Course

Falcon Training PMP & CAPM Exam Preparation Course Falcon Training PMP & CAPM Exam Preparation Course Chapter 1-3: Project Framework Review Questions 1. What is the primary role of the portfolio manager? A. To deliver the unique product, service, or result

More information

Does This Come With Instructions?

Does This Come With Instructions? Does This Come With Instructions? Creating A Manual for Your Organization s Project Culture Russell Rivenbark M.P.M. RCDD, PMP New Hanover County Schools First, have a definite, clear practical ideal;

More information

Agency and Internal Labeling

Agency and Internal Labeling Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the

More information

PRINCE2 VS PMBOK FRIEND OR FOE WOULDN T IT BE NICE:

PRINCE2 VS PMBOK FRIEND OR FOE WOULDN T IT BE NICE: PRINCE2 VS PMBOK FRIEND OR FOE A presentation to: PMI Vancouver Island Chapter May 21, 2009 Presented by: Julie Grabb PMP Prince2 Practitioner Prince2 Authorized Trainer WOULDN T IT BE NICE: Let the Project

More information

Mentored Course Plan PMP (2013 version)

Mentored  Course Plan PMP (2013 version) Module 1 Key Concepts Course overview What is a project? What is Project Management? The performing organisation o Project Management Office (PMO) Structure of the PMBOK o PM processes and process groups

More information

Intensive Course Plan CAPM 5 (2013 version)

Intensive Course Plan CAPM 5 (2013 version) Module 1 Key Concepts Course overview What is a project? What is Project? Project Office (PMO) Structure of the PMBOK o PM processes and process groups o IPECC o Process Interactions o Process Mapping

More information

PROGRAM MANAGEMENT PLANS AT TXDOT

PROGRAM MANAGEMENT PLANS AT TXDOT PROGRAM MANAGEMENT PLANS AT TXDOT Transportation Programs Division PPM Fort Worth District Bryan District 6/6/18 Outline 1 Introduction to management plans 3-4 2 FHWA project management plans 5-7 3 4 5

More information

PM tutor. Manage Project Team Part 1. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence. Powered by POeT Solvers Limited

PM tutor. Manage Project Team Part 1. Presented by Dipo Tepede, PMP, SSBB, MBA. Empowering Excellence. Powered by POeT Solvers Limited PM tutor Empowering Excellence Manage Project Team Part 1 Presented by Dipo Tepede, PMP, SSBB, MBA This presentation is copyright 2009 by POeT Solvers Limited. All rights reserved. This presentation is

More information

The Practice of Integrated Change Control in Engineering Projects. Rakesh Patel, P.E., PMP

The Practice of Integrated Change Control in Engineering Projects. Rakesh Patel, P.E., PMP The Practice of Integrated Change Control in Engineering Projects Rakesh Patel, P.E., PMP Show of Hands Who all Manages Projects? What is Change Management? Change management is proactive management of

More information

HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?

HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency

More information

Project Management Body of Knowledge Chapter 3 Project Processes

Project Management Body of Knowledge Chapter 3 Project Processes Project Management Body of Knowledge Chapter 3 Project Processes PMP Exam Prep PMBOK Chapter 1 - Introduction Chapter 2 - Organizational Influences & Life Cycles Chapter 3 - Project Processes Chapter 3

More information

ASA380 ASAP Methodology for Implementation in Details

ASA380 ASAP Methodology for Implementation in Details ASAP Methodology for Implementation in Details SAP Solution Manager Course Version: 95 Course Duration: 3 Day(s) Publication Date: 01-03-2013 Publication Time: 1007 Copyright Copyright SAP AG. All rights

More information

Project Management in Clinical Trials. Presented by: Melanie Gentgall and Tim Dyke

Project Management in Clinical Trials. Presented by: Melanie Gentgall and Tim Dyke Project Management in Clinical Trials Presented by: Melanie Gentgall and Tim Dyke We acknowledge the traditional custodians of the land on which we meet today, and pay respect to their elders past, present

More information

Project Management Framework with reference to PMBOK (PMI) July 01, 2009

Project Management Framework with reference to PMBOK (PMI) July 01, 2009 Project Management Framework with reference to PMBOK (PMI) July 01, 2009 Introduction Context Agenda Introduction to Methodologies What is a Methodology? Benefits of an Effective Methodology Methodology

More information

9th Annual SAS Health Care & Life Sciences Executive Conference

9th Annual SAS Health Care & Life Sciences Executive Conference : An Integrated Platform to Promote Data Exchange, Collaboration, and Advanced Analytics 9th Annual SAS Health Care & Life Sciences Executive Conference 9-10 May 2012 Bernd Doetzkies, Director Informatics

More information

QbD approach and Regulatory Challenges in Europe

QbD approach and Regulatory Challenges in Europe QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views

More information

Risk-Based Monitoring - Prospective from CRO

Risk-Based Monitoring - Prospective from CRO Risk-Based Monitoring - Prospective from CRO New Trends in Clinical Trials Taipei 2016 Tong Guo, PhD Head of Biostatistics, Africa & Asia QuintilesIMS Copyright 2015 Quintiles Disclaimer The views and

More information

Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer

Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following

More information

III PMF MANAGEMENT SOLUTIONS. Course Number Project Management Course Overview

III PMF MANAGEMENT SOLUTIONS. Course Number Project Management Course Overview III PMF MANAGEMENT SOLUTIONS Course Number Project Management Course Overview House Keeping Beep beep (prepare to evacuate): Whoop whoop (evacuate): Follow the red hat (fire warden). Designated evacuation

More information

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Impact of MRCT after ICH E17 fully implement -Industry perspective- Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation

More information

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types

More information

Project Management CSC 310 Spring 2018 Howard Rosenthal

Project Management CSC 310 Spring 2018 Howard Rosenthal Project Management CSC 310 Spring 2018 Howard Rosenthal 1 Notice This course is based on and includes material from the text: A User s Manual To the PMBOK Guide Authors: Cynthia Stackpole Snyder Publisher:

More information

Agile Program Management in Action

Agile Program Management in Action Agile Program Management in Action Agile Program Management in Action PRESENTATION CUTOUT PEOPLE SAMPLER Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the

More information

The Planning Process Group

The Planning Process Group Assalam-o-alaikum Project Management Process Groups Project Integration Management Knowledge Areas Initiating Planning Executing Scope Time Cost Quality Human Resources Communications Monitoring & Controlling

More information

PMP PMBOK 5 th Edition Course Agenda

PMP PMBOK 5 th Edition Course Agenda PMP PMBOK 5 th Edition Course Agenda 1. Introduction to PMP Course Certification What are PMI and PMP Application Requirements for the PMP Exam Guidelines to Fill Up the PMP Application About the PMP Exam

More information

PRINCE2 and the National and International Standards

PRINCE2 and the National and International Standards PRINCE2 and the National and International Standards Robert Buttrick, Project Workout Limited White Paper December 2012 2 PRINCE2 and the National and International Standards Contents 1 Introduction 3

More information

An Oracle White Paper October Why Projects Fail: Avoiding the Classic Pitfalls

An Oracle White Paper October Why Projects Fail: Avoiding the Classic Pitfalls An Oracle White Paper October 2010 Why Projects Fail: Avoiding the Classic Pitfalls Executive Summary There is an age-old saying that goes something like this: we can do anything we want, but we cannot

More information

Similarity Assessment of Biosimilars. The Past, Present and Future State. Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016

Similarity Assessment of Biosimilars. The Past, Present and Future State. Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016 Similarity Assessment of Biosimilars. The Past, Present and Future State Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016 Disclaimer The views and opinions expressed in the following PowerPoint

More information

Project Integration Management

Project Integration Management Project Integration Management Presented by Project Masters Inc. *Throughout this presentation, we reference and recognize the following trademarks, service marks, and copyrights of the Project Management

More information

PMP in the Real World. Scott Bailey, MBA, PMP, SSGB

PMP in the Real World. Scott Bailey, MBA, PMP, SSGB PMP in the Real World Scott Bailey, MBA, PMP, SSGB PMP in the Real World Webinar purpose To understand the relevance of the PMI PMP certification and its influence on the success or failure of projects

More information

Project Management Framework

Project Management Framework Project Management Framework Study Notes PMI, PMP, CAPM, PMBOK, PM Network and the PMI Registered Education Provider logo are registered marks of the Project Management Institute, Inc. Points to Note Please

More information

Project Management Professional (PMP) Exam Prep Course 00 PMP Application & Exam

Project Management Professional (PMP) Exam Prep Course 00 PMP Application & Exam Project Management Professional (PMP) Exam Prep Course 00 PMP Application & Exam Slide 1 Application & Exam Types of Questions PM Basics Ten Knowledge Areas Professional Responsibility Practice Exams Slide

More information